Hepatocellular Carcinoma Clinical Trials in Nanjing, Jiangsu
22 recruitingNanjing, Jiangsu, China
Showing 1–20 of 22 trials
Recruiting
Phase 1
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
Unresectable Hepatocellular Carcinoma (HCC)Hepatoma
Suzhou Mednovo Yi Medical Technology Co., Ltd.40 enrolled8 locationsNCT07391839
Recruiting
Phase 2
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
HCC - Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.75 enrolled1 locationNCT07310173
Recruiting
Phase 2
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Hepatocellular Carcinoma (HCC)
Abbisko Therapeutics Co, Ltd141 enrolled51 locationsNCT07327034
Recruiting
Phase 2
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Peking Union Medical College Hospital158 enrolled3 locationsNCT07317414
Recruiting
Not Applicable
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Nanjing Tianyinshan Hospital300 enrolled1 locationNCT06893887
Recruiting
Phase 3
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
Unresectable Hepatocellular Carcinoma
Chengdu New Radiomedicine Technology Co. LTD.108 enrolled11 locationsNCT06900543
Recruiting
Not Applicable
SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
Unresectable Hepatocellular Carcinoma
Zhongda Hospital108 enrolled1 locationNCT06909708
Recruiting
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without HAIC for Advanced HCC
Hepatocellular Carcinoma (HCC)
Zhongda Hospital900 enrolled1 locationNCT06881433
Recruiting
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions
Hepatocellular Carcinoma (HCC)
Zhongda Hospital1,200 enrolled1 locationNCT06881446
Recruiting
Phase 3
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
Akeso469 enrolled4 locationsNCT06371157
Recruiting
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Hepatocellular Carcinoma (HCC)
Zhongda Hospital300 enrolled2 locationsNCT06876753
Recruiting
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
Combined Hepatocellular-cholangiocarcinomaCombined Hepatocellular Carcinoma and CholangiocarcinomaCombined Hepatocellular and Cholangiocarcinoma
Zhongda Hospital198 enrolled1 locationNCT06849180
Recruiting
Phase 2
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
Hepatocellular Carcinoma (HCC)Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation
The First Affiliated Hospital with Nanjing Medical University276 enrolled1 locationNCT06762782
Recruiting
Phase 3
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Hepatocellular CarcinomaImmunotherapyPreoperative
The First Affiliated Hospital with Nanjing Medical University130 enrolled1 locationNCT05613478
Recruiting
Not Applicable
Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma
Zhongda Hospital5 enrolled1 locationNCT06694636
Recruiting
Not Applicable
Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University100 enrolled1 locationNCT05887661
Recruiting
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Hepatocellular Carcinoma
Zhongda Hospital444 enrolled1 locationNCT06669377
Recruiting
Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
Hepatocellular Carcinoma
Zhongda Hospital950 enrolled1 locationNCT06607120
Recruiting
Immunotherapy for Hepatocellular Carcinoma
Hepatocellular CarcinomaImmunotherapy
The First Affiliated Hospital with Nanjing Medical University11,000 enrolled1 locationNCT06241326
Recruiting
Not Applicable
DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
Hepatocellular Carcinoma
Zhongda Hospital188 enrolled2 locationsNCT06190665